Source-grounded facts extracted from RxSight, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RxSight, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-16 meeting.
“3. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 33,062,585 92,653 143,954 —”
RxSight, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-16 meeting.
“2. Advisory Vote on Executive Compensation. The stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement based on the following results of voting: For Against Abstain Broker Non-Votes 21,236,615 2,742,189 43,385 9,277,003”
RxSight, Inc. shareholders approved Election of Three Class II Directors at the 2026-06-16 meeting.
“1. Election of Three Class II Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class II directors to hold office until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified: Nominee For Against Abstain Broker Non-Votes William J. Link 21,086,793 — 2,935,396 9,277,003 Robert Warner 15,667,180 — 8,355,009 9,277,003 Shweta Singh Maniar 13,850,389 — 10,171,800 9,277,003”
RxSight, Inc. reported the quarter ended March 31, 2026 results: revenue sales of $30.9 million, net income net loss of $(15.9) million, EPS $(0.38) per basic and diluted share. Guidance reaffirmed.
“– May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments • Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units • 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units • Robust clinical data presented at”
RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters") valued at approximately $93.2 million (effective 2024-05-08).
“On May 8, 2024, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 1,785,714 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).”
RxSight, Inc. reported the three months ended March 31, 2024 results: revenue $29.5 million, net income $(9.1) million, EPS $(0.25) per basic and diluted share. Guidance raised.
“following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights • Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: • The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+TM), representing a 92% increase in procedure volume”
RxSight, Inc. amended 100 Columbia Amendment with Accuride International Inc. valued at $64,843 per month (effective 2024-04-18).
“On April 18, 2024, the Company entered into a Fifth Amendment to that certain Commercial Lease Agreement, dated August 31, 2015, as amended November 23, 2015, December 22, 2015, January 18, 2016, and November 12, 2016, with Accuride International Inc., for the property located at 100 Columbia in Aliso Viejo, California (the “100 Columbia Amendment”).”
RxSight, Inc. amended 5 Columbia Amendment with Clifford D. Downs valued at $30,701 per month (effective 2024-04-18).
“On April 18, 2024, the Company entered into Lease Amendment #2 to that certain Lease Agreement dated January 10, 2018, as amended on April 5, 2022, with Clifford D. Downs, for the property located at 5 Columbia in Aliso Viejo, California (the “5 Columbia Amendment”).”
RxSight, Inc. entered into 125 Columbia Lease with BML Management, LLC valued at $41,579 per month (effective 2024-04-18).
“On April 18, 2024, the Company entered into a Standard Industrial/Commercial Single-Tenant Lease – Net (the “125 Columbia Lease”) with BML Management, LLC, for an approximately 26,825 square foot industrial and research and development facility in Aliso Viejo, California.”
RxSight, Inc. updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).
“On February 28, 2024, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2023.”
RxSight, Inc. reported the fiscal year ending December 31, 2024 results: revenue $128.0 million to $135.0 million. Guidance initiated.
“RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million”
RxSight, Inc. reported the fiscal year ended December 31, 2023 results: revenue approximately $89.1 million.
“Preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1 million”
RxSight, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.6 million.
“Preliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million”
RxSight, Inc. reported three and nine months ended September 30, 2023 results: revenue $22.2 million, net income $(12.4) million, EPS $(0.35) per basic and diluted share. Guidance raised.
“cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights • Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: • The sale of 66 Light Delivery Devices (LDDTMs), representing a 35% increase in unit sales compared to the”
RxSight, Inc. reported three and six months ended June 30, 2023 results: revenue $20.8 million, net income $(13.8) million, EPS $(0.40) per basic and diluted share. Guidance raised.
“following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights • Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: • The sale of 67 Light Delivery Devices (LDDTMs), representing a 37% increase in unit sales compared to”
RxSight, Inc. incurred loan of $20.0 million in aggregate Term A Loans and up to $40.0 million in additional term loans available in four tranches with Oxford Finance, LLC as collateral agent and the lenders party thereto at floating per annum rate equal to the greater of 1-Month Term SOFR or 5.15% plus maturing June 1, 2028.
“On June 30, 2023, the Company entered into a new Loan and Security Agreement (“New LSA”) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $20.0 million in aggregate Term A Loans (the “Term A Loans”).”
RxSight, Inc. terminated Retired LSA with Oxford Finance, LLC (effective 2023-06-30).
“On June 30, 2023, the Company prepaid the Retired Term Loan using a combination of cash, primarily comprised of cash raised under the ATM Facility during the quarter ended June 30, 2023, and the Term A Loans (defined below) of $20.0 million.”
RxSight, Inc. entered into New LSA with Oxford Finance, LLC valued at $20.0 million (effective 2023-06-30).
“On June 30, 2023, the Company entered into a new Loan and Security Agreement (“New LSA”) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $20.0 million in aggregate Term A Loans (the “Term A Loans”).”
RxSight, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“3. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 29,491,614 3,150 115,168 —”
RxSight, Inc. shareholders approved Amendment of the Company's certificate of incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-01 meeting.
“2. Amendment of the Company's certificate of incorporation to reflect new Delaware law provisions regarding officer exculpation. The amendment of the Company's certificate of incorporation to reflect new Delaware law provisions regarding officer exculpation was approved based on the following results of voting: For Against Abstain Broker Non-Votes 22,214,405 2,173,831 26,626 5,195,070”
RxSight, Inc. shareholders approved Election of Three Class II Directors at the 2023-06-01 meeting.
“1. Election of Three Class II Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class II directors to hold office until our 2026 annual meeting of stockholders and until their successors have been duly elected and qualified: Nominee For Withhold Broker Non-Votes William J. Link, Ph.D. 24,161,853 253,009 5,195,070 Robert Warner 21,883,075 2,531,787 5,195,070 Shweta Singh Maniar 21,198,960 2,215,902 5,195,070”
RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).
“In the first quarter of 2023, total revenue was $17.5 million, an increase of 96% compared to $8.9 million in the first quarter of 2022.”
RxSight, Inc. reported the three and twelve-months ended December 31, 2022 results: revenue $16.1 million, net income $(15.6) million, EPS $(0.56) per basic and diluted share. Guidance initiated.
“today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Full Year Highlights • Recognized fourth quarter 2022 revenue of $16.1 million, an increase of 91% compared to the fourth quarter of 2021, reflecting: • The sale of 57 Light Delivery Devices (LDDTMs), representing a 27% unit increase from the fourth quarter”
RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters valued at approximately $46.7 million (effective 2023-02-07).
“On February 7, 2023, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative (the “Representative”) of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 4,000,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).”
RxSight, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $16.1 million.
“operational results for the fourth quarter and full-year 2022. Preliminary Unaudited Results • Preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by: o The sale of 57 Light Delivery Devices (LDDTMs), expanding the installed base to 400 LDDs”
RxSight, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting procedures, and conform to DGCL amendments (effective 2022-12-09).
“On December 9, 2022, the Board of Directors (the “Board”) of RxSight, Inc. (the “Company”), acting upon the recommendation of the Corporate Governance and Nominating Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.”
RxSight, Inc. reported three and nine months ended September 30, 2022 results: revenue $12.6 million, net income $(16.8) million, EPS $(0.61) per basic and diluted share. Guidance raised.
“cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: • Delivered third quarter 2022 revenue of $12.6 million, an increase of 118% compared to the third quarter of 2021, reflecting: • The sale of 49 Light Delivery Devices (LDDTMs), representing a 58% unit increase from the third quarter”
Tamara Fountain, M.D. was appointed as Director at RxSight, Inc..
“On December 29, 2021 the board of directors (the “Board”) of RxSight, Inc. (the “Company”) increased the number of its authorized directors from seven to nine, and appointed Shweta Singh Maniar and Tamara Fountain, M.D. to fill the two newly created openings on the Board, effective December 31, 2021 and January 1, 2022, respectively.”
Shweta Singh Maniar was appointed as Director at RxSight, Inc..
“On December 29, 2021 the board of directors (the “Board”) of RxSight, Inc. (the “Company”) increased the number of its authorized directors from seven to nine, and appointed Shweta Singh Maniar and Tamara Fountain, M.D. to fill the two newly created openings on the Board, effective December 31, 2021 and January 1, 2022, respectively.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.